Drug intelligence / Profile preview

CYT X500

Development stage: Preclinical
Lead developer: Cytospire Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

CYT X500 is a preclinical-stage, bispecific pan-gamma-delta (pan-γδ) T-cell engager (TCE) being developed by Cytospire Therapeutics for the treatment of autoimmune diseases. The therapeutic is designed to recruit and direct pan-γδ T cells against cells expressing a specific, undisclosed autoimmune antigen, thereby modulating or eliminating pathogenic cells involved in autoimmunity.

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on CYT X500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYT X500.

Explore the full profile